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Background: Cellular senescence is linked to aging and tumorigenesis. The senescence of mesenchymal stem cells
(MSCs) may influence the tumor growth, metastasis, and angiogenesis by secreting a variety of cytokines and
growth factors.
Results: The conditioned media of adipose derived MSCs (AD-MSCs) stimulated the proliferation of human LoVo
colorectal-cancer cells, and the replicative senescent MSCs had the more obvious effects in comparison to that of
premature AD-MSCs. Analysis of the factors secreted in the MSCs culture media determined that senescent MSCs
expressed and secreted high levels of galectin-3. Galectin-3 expression correlated with the stimulatory effect of
senescent AD-MSCs on LoVo cells proliferation, as knockdown of galectin-3 in senescent AD-MSCs significantly
reversed the effect of MSCs–mediated growth stimulation of LoVo cells. Furthermore, the simultaneous addition
of recombinant galectin-3 to the co-culture systems partially restored the tumor-promoting effect of the senescent
AD-MSCs. Analysis of the mechanisms of senescent MSCs and galectin-3 on LoVo cells signal transduction determined
that senescent MSCs and exogenous galectin-3 promoted cell growth by activating the mitogen-activated protein
kinase (MAPK) (extracellular signal-regulated kinase [ERK]1/2) pathway.
Conclusions: Senescent MSCs may alter the tissue microenvironment and affect nearby malignant cells via cytokine
secretion, and galectin-3 is an important mediator of senescent AD-MSC–mediated stimulation of colon cancer cell
growth. Therefore, thorough assessment of AD-MSCs prior to their implementation in clinical practice is warranted.
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Cellular senescence, a state of irreversible growth arrest,
can be triggered by many mechanisms, including telo-
mere shortening, epigenetic derepression of the cyclin-
dependent kinase inhibitor 2A/ADP ribosylation factor
(INK4a/ARF) locus, and DNA damage [1]. Cellular sen-
escence is linked to aging and tumorigenesis, and has
been proposed as a suppressive mechanism against the
development of cancer [2, 3]. However, recent studies
have revealed that cellular senescence also has tumor-
promoting effects, and the accumulation of senescent* Correspondence: lyj8181@163.com
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article, unless otherwise stated.cells during the aging process in vivo may contribute to
the age-related increase in cancer incidence [4].
Mesenchymal stem cells (MSC), which possess broad
and potent multilineage differentiation potential and
potent immunoregulatory properties, are the optimal
source for stem cell transplant in clinical applications [5, 6].
Similar to other adult somatic cells, long-term culture
in vitro leads to MSC senescence, which results in
growth arrest and reduced differentiation [7, 8]. The
replicative senescence of MSCs is evinced by telomere
shortening, enlargement and flattening of the charac-
teristic stem cell morphology, reduced proliferation
rate, and altered secretory profile [8, 9]. The function
of adult tissue-specific stem cells declines with age, and
aged MSCs could be more deleterious as they can greatlydistributed under the terms of the Creative Commons Attribution 4.0
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aged patients with coronary artery disease have impaired
angiogenic potential and reduced proangiogenic factor se-
cretion [11]. Senescent MSCs may contribute to the
physiological decline in tissue homeostasis and to the in-
creased risk of neoplasm during aging [9].
Recently report showed that MSCs stimulated inva-
sion, survival and tumorigenesis of colorectal cancer
cells through the release of soluble NRG1, activating the
HER2/HER3-dependent PI3K/AKT signalling cascade in
colorectal cancer cells [12]. In this study, we showed that
replicative senescent AD-MSCs significantly promoted
the proliferation of LoVo colorectal-cancer cells in com-
parison to premature AD-MSCs, and the expression of
galectin-3, a powerful modulator of cell migration and
spread in carcinoma cells, correlated with the stimula-
tory effect of senescent AD-MSCs on colorectal cancer
cells proliferation. Therefore, thorough assessment of




In the first few generations, the AD-MSCs exhibited
fibroblast-like morphology. After 30 passages, the MSCs
appeared longer and larger, with accumulation of granu-
lar cytoplasmic inclusions. The percentage of positive
SA-β-Gal staining was increased significantly in the rep-
licative P30-MSCs (Fig. 1a). The AD-MSCs were also
capable of osteogenic and adipogenic differentiation
when cultured in the appropriate inducing media. As-
sessment of the degree of osteogenic and adipogenic dif-
ferentiation via Alizarin Red S and Oil Red O staining,
respectively, revealed a sharp decline in the adipogenic
and osteogenic potential of P30-MSCs compared to P3-
MSCs (Fig. 1b). CCK-8 analysis showed that the prolifer-
ation potential of AD-MSCs declined significantly with
cell replicative passaging (Fig. 1c). Western blot analysis
of p53 and p21 expression in the AD-MSCs showed that
p53 and p21 expression increased gradually with passage
(Fig. 1d). Flow cytometric analysis demonstrated that
both P3-MSCs and P30-MSCs were positive for CD73,
CD90, and CD105, and negative for CD34, CD45, and
HLA-DR (data not shown).
CM-P30 promoted colon cancer cell proliferation
To determine the effect of P30-MSCs on colon cancer
cell growth, LoVo cells were cultured with concentrated
CM-P3 or CM-P30 for 48 h. As shown in Fig. 2a-c, the
conditioned medium of MSCs can promoted LoVo cell
proliferation, and the LoVo cells cultured with CM-P30
spread and grew faster than cells cultured with culture
medium alone or with CM-P3. However if the cells were
incubated for 48 h, both of CM-P3 and CM-P30 treatedcolon cancer cell groups achieved similar proliferation
levels.Galectin-3 contributed to P30-MSC stimulation of colon
cancer cell growth
Accumulated evidence indicates that galectin-3 is closely
involved in tumor cell proliferation, transformation, migra-
tion, invasion, and metastasis [13]. We analyzed galectin-3
expression in CM-P3 or CM-P30 with quantitative PCR
(Q-PCR) and ELISA, and found that both mRNA and pro-
tein levels of galectin-3 were significantly upregulated in
the AD-MSCs during senescence (Fig. 3a-b), suggesting
that galectin-3 may have been involved in the P30-MSC–
mediated growth stimulation of LoVo cells.
To examine whether galectin-3 secretion in P30-MSCs
stimulates LoVo cell proliferation, we blocked galectin-3
expression in P30-MSCs with a galectin-3–specific
siRNA. Q-PCR and ELISA data showed that LGALS3
mRNA expression was decreased and that galectin-3 se-
cretion in CM-P30 was significantly reduced following
siRNA treatment (Fig. 3c, d).
LoVo cells were incubated with 50 or 100 ng/ml recom-
binant galectin-3 for 24 hours, and the proliferation of
LoVo cells were evaluated by CCK-8. As Fig. 4a showed
that the rgalectin-3 enhanced the growth of LoVo cells.
LoVo cells were then incubated with CM-P30 pre-treated
with the galectin-3 siRNA or NC, and the knockdown of
galectin-3 in senescent AD-MSCs significantly reversed
the effect of MSCs–mediated growth stimulation of LoVo
cells (Fig. 4b). Furthermore, the simultaneous addition of
100 ng/ml recombinant galectin-3 to the co-culture sys-
tems partially restored the tumor-promoting effect of the
senescent AD-MSCs.P30-MSCs promoted ERK1/2 activation in colon cancer
cells
As reported previously [14], exogenous galectin-3 induces
the extracellular signal-regulated kinases (ERK1/2) phos-
phorylation in cancer cells, and the activation of ERK1/2
are associated with cancer cell proliferation and survival
[15, 16]. Our western blot data were showed in Fig. 5a, the
CM of MSCs promoted ERK1/2 phosphorylation in the
LoVo cells and that CM-P30 had a greater stimulative ef-
fect on ERK1/2 activation. Moreover, the phosphorylation
of ERK1/2 induced by CM-P30 of MSCs were aborted by
U0126, the specific inhibitor of MEK1/2, suggesting that
the signal was transferred through a specific Raf-MEK1/2-
ERK1/2 pathway to activate ERK1/2. We then knocked
down galectin-3 expression in the P30-MSCs and com-
pared the promoter effect of the CM-P30 on ERK1/2
phosphorylation to that of the CM of MSCs treated with
MSCNC. Galectin-3 knockdown diminished the CM-P30–
induced ERK1/2 phosphorylation; however, the addition of
Fig. 1 Characterization of senescent AD-MSCs. (a) SA-β-Gal staining of senescent MSCs (P30 AD-MSCs) or pre-senescent MSCs (P3 AD-MSCs).
(b) Oil Red O and Alizarin red staining of differentiated AD-MSCs. (c) The proliferation potential of AD-MSCs by CCK-8 analysis. (d) Western blot
analysis of AD-MSC P21 and P53 expression. GAPDH, glyceraldehyde-3-phosphate dehydrogenase internal control
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tion in the LoVo cells (Fig. 5b).
Discussion
Recent studies have shown that a pool of molecules se-
creted by senescent cells, referred to as having the
senescence-associated secretory phenotype (SASP), is
associated with arrest of cell proliferation and may
contribute to it via the autocrine/paracrine pathways
[10, 17]. Our data revealed that the MSCs had the typical
senescence-associated characteristics and SASP after re-
peated passage, marked by the appearance of senescence-associated morphological features, decreased proliferation,
SA-β-Gal positivity, induced p53 and p21 expression, and
increased galectin-3 expression. We then showed that
CM-P30 promoted colon cancer cell proliferation. In the
co-culture experiments, we demonstrated that galectin-3
mediated the promoter effects of AD-MSCs on colon can-
cer cell proliferation to some extent, as specific knock-
down of galectin-3 with siRNA significantly reversed the
MSC-mediated stimulation of colon cancer cell growth.
The tumor microenvironment is increasingly regarded
as an important regulator of malignant progression of can-
cer cells [18]. MSCs may secrete a variety of cytokines and
Fig. 2 The CM of AD-MSCs promotes LoVo cell proliferation in vitro. (a) Morphology of LoVo cells incubated with the CM of AD-MSCs for 24 h. (b)
The proliferation assays of LoVo cell with CM of AD-MSCs for 24 h. (c) The proliferation assays of LoVo cell with CM of AD-MSCs for 12 h, 24 h and 48 h. All
experiments were repeated at least three times, normal DMEM without cell medium (DMEM) was used as the control. ***P < 0.001 versus control;
#P < 0.05, P3-MSC versus P30-MSC
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and angiogenesis [19, 20]. Karnoub et al. [19] showed that
MSCs play a pivotal role in colon cancer progression and
metastasis; when recruited into breast cancer stroma,
bone marrow MSCs tended to facilitate breast cancer cell
metastasis and regulate cancer stem cell behavior via the
secretion of the chemokine CCL5. Recent studies have
shown that the CM of MSCs enhances tumor growth, in-
dicating that the factors secreted by MSCs have profound
effects on “reprogramming” tumor growth [18, 21], and
the senescent umbilical cord MSCs promoted the prolifer-
ation and migration of breast cancer cells [22].
Of the MSC SASP factors, we found that galectin-3 was
an important mediator of cancer-promoting activity. A
unique chimera-type member of the β-galactoside–binding
soluble lectin family with a molecular mass of 29–35 kD,
galectin-3 is implicated in a variety of biological functions
[23, 24]. Previously, Liu et al. showed that galectin-3 is se-
creted into the CM of UC-MSCs and is involved in theimmunosuppressive function of UC-MSCs [25]. In
addition, galectin-3 expression in most cancer cells is in-
creased, and is associated with growth and metastases in
pancreatic and breast cancer systems [26]. A recent report
[27] showed that galectin-3 is involved in the nicotine-
induced promotion of apoptosis resistance of breast cancer
cells and that it promotes cancer cell growth and protects
cells from apoptosis induced by chemotherapeutic drugs.
Baptiste et al. [28] showed that galectin-3 was a powerful
modulator of cell adhesion and spread in breast carcinoma
cells and that the exogenous addition of recombinant
galectin-3 promoted the growth of galectin-3–null cells.
However, our data showed that recombinant galectin-3 has
a weaker effect on cancer cell growth than senescent
MSCs, suggesting that other cytokines secreted from sen-
escent MSCs may be associated with the stimulation of
colon cancer cell growth.
Lastly, we analyzed the mechanisms of senescent MSCs
and galectin-3 on colon cancer cell signal transduction,
Fig. 3 Galectin-3 expression in P3-MSC or P30-MSC. (a) LGALS3 mRNA expression in P3-MSCs or P30-MSCs. (b) Galectin-3 protein levels in the CM
of AD-MSCs. (c) Decreased expression of LGALS3 mRNA in P30-MSCs following treatment with galectin-3 siRNA. (d) Decreased expression of
galectin-3 protein in CM-P30 following treatment with galectin-3 siRNA. MSCgal-3▼, MSCs treated with galectin-3 siRNA; MSCNC, MSCs treated
with negative control of siRNA. All experiments were repeated at least three times. **P < 0.01, P3-MSC versus P30-MSC; ###P < 0.001, MSCNC
versus MSCgal-3▼
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promoted colon cancer cell growth by activating the
MAPK (ERK1/2) pathway. The extracellular signal-
regulated kinases (ERK1/2) which are serine/threonine
protein kinases, as one of the most important regulator of
key cellular processes [15], involved in carcinogenesis
due to their ability to stimulate cell proliferation and
survival [16]. The MAPK pathways are activated by di-
verse extracellular and intracellular stimuli including
peptide growth factors, cytokines, hormones, and vari-
ous cellular stressors [29]. Gao et al. [14] showed that
exogenous galectin-3 induces ERK1/2 phosphorylation
in cancer cells, and our results are consistent with this
reports.
In summary, our study suggests that senescent MSCs
may alter the tissue microenvironment and affect nearby
malignant cells via cytokine secretion, and that galectin-3
is an important mediator of senescent AD-MSC–mediated
stimulation of colon cancer cell growth. Therefore, thor-
ough assessment of AD-MSCs prior to their implementa-
tion in clinical practice is warranted.Materials and methods
Isolation and preparation of senescent AD-MSCs
The AD-MSCs were isolated and obtained by density gradi-
ent centrifugation, approved by the Ethics Committee of
the Affiliated Hospital of Guiyang Medical College. Briefly,
AD-MSCs were isolated and cultured according to a colla-
genase digestion protocol. Mononuclear cells were plated
in α-minimum essential medium (Invitrogen, Carlsbad,
CA, USA) containing 10 % fetal bovine serum (FBS)
(HyClone, Utah, USA), and cultured in a humidified incu-
bator containing 5 % CO2 at 37 °C.
AD-MSCs were further cultivated to confluence and were
amplified, and replicative senescent cells were passaged
serially over 30 passages when the typical senescence-
associated morphological features appeared. Passage 3 (P3)
and P30 cells were referred to as “young” (P3-MSCs) and
“senescent” MSCs (P30-MSCs), respectively.
Characterization of senescent AD-MSCs
Senescence-associated β-galactosidase (SA-β-Gal) stain-
ing was performed using an SA-β-Gal staining kit (Cell
Fig. 4 Galectin-3 is an important mediator of P30-MSC–mediated stimulation of LoVo cell growth. (a) Proliferation of LoVo cells incubated with
50 or 100 ng/ml recombinant galectin-3. (b) Proliferation of LoVo cells incubated with CM of P30-MSCs, which treated with galectin-3 siRNA or
NC. Control, normal DMEM without cell medium; siGal-3, galectin-3 siRNA; rgalectin-3, recombinant galectin-3. All experiments were repeated at
least three times. *P < 0.05,**P < 0.01 versus control; ##P < 0.01, versus siGAL-3
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the manufacturer’s instructions. For the proliferation
analysis, MSCs were counted every 24 hours for 5 days
using a cell counting kit-8 (CCK-8) (DoJinDo, ShangHai,
China). All experiments were performed three times.
AD-MSCs surface marker analysis by flow cytometry was
performed on a FACSCalibur unit (Becton DickinsonFig. 5 Western blot analysis of P30-MSC and exogenous galectin-3 promot
ERK1/2 phosphorylation in the LoVo cells, which were aborted by U0126 fo
which treated with or without galectin-3 siRNA.siGal-3, galectin-3 siRNA; rg
control. All experiments were repeated at least three times. ##P < 0.01 versuBiosciences, San Jose, CA, USA); cells were stained with
phycoerythrin-conjugated antibodies against CD105, CD73,
CD90, CD45 and HLA-DR (Becton Dickinson Biosciences).
For osteogenic and adipogenic differentiation, MSCs were
incubated with MesenCult Osteogenic or Adipogenic
Stimulatory Medium (STEMCELLTechnologies, Vancouver,
Canada) for 2–3 weeks. Osteogenic and adipogenicion of ERK1/2 activation in LoVo cells. (a) the CM of MSCs promoted
r 60 min treatment. (b) LoVo cells incubated with CM of P30-MSCs,
alectin-3, recombinant galectin-3; GAPDH was used as the internal
s control; **P < 0.01 versus siGAL-3
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Red O (Sigma-Aldrich, St. Louis, MO, USA) staining,
respectively.
p21 and p53 protein levels were analyzed by western
blotting. Proteins were extracted from 1 × 106 P3-MSCs or
P30-MSCs with 1 ml radioimmunoprecipitation assay
(RIPA) buffer (Sigma-Aldrich), separated by 10 % sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE), and transferred to Immobilon polyvinyl difluoride
(PVDF) membranes. The membranes were incubated with
antibody against p21 and p53 (Abcam, Cambridge, MA,
USA), followed by goat anti-rabbit horseradish peroxid-
ase (HRP)-conjugated antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), and visualized with
SuperSignal West Pico Chemiluminescent Substrate
(Millipore, Billerica, MA, USA).
Preparation of conditioned medium
To harvest the MSC conditioned medium (CM), 80 %
confluent P3-MSC and P30-MSC cultures were exten-
sively washed with phosphate-buffered saline (PBS) and
incubated in serum-free culture medium for 24 h. Then,
the CM from the P3-MSCs (CM-P3) and P30-MSCs
(CM-P30) was collected and concentrated to 1/2× volume
with an ultra-filtration membrane with a molecular weight
cut-off of 3 kD by centrifuging at 5000 rpm for 30 min at
4 °C. The concentrated CM was then filtered through a
0.22-μm membrane and stored at −80 °C until used.
Cell proliferation assay of colon cancer cells
The human LoVo colon cancer cell line was obtained
from the American Type Culture Collection (ATCC).
LoVo cells were established from a metastatic nodule
resected from a 56-year-old Caucasian male colorectal
adenocarcinoma patient [30].
The LoVo cells were cultured in phenol red-free
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen,
Carlsbad, CA, USA) supplemented with 10 % FBS; 2.5 ×
103 cells/well were plated in 200μl growth medium in 96-
well plates. After 24 h, the medium was replaced with con-
centrated conditioned medium of CM-P3 and CM-P30 as
for 12h, 24 h or 48 h. Tumor cell proliferation was evalu-
ated using Cell Counting Kit-8 according to the manufac-
turer’s instructions.
Analysis of galectin-3 expression in MSCs
We analyzed galectin-3 (LGALS3) mRNA expression with
real-time PCR: total RNA was isolated from 1 × 106 P3-
MSCs or P30-MSCs using TRIzol (Invitrogen) according
to the manufacturer’s instructions. First-strand comple-
mentary DNA was reverse-transcribed using a Reverse
Transcriptase MIX Kit (Toyobo, Osaka, Japan). Quantita-
tive real-time PCR was performed in an ABI 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City,CA, USA) using Fast SYBR Green PCR Master Mix (Ap-
plied Biosystems). We used the following primer pairs as
reported previously [31]: β-actin (forward: 5′-GAAGGTG
AAGGTCGGAGTCA-3′, reverse: 5′-GAAGATGGTGA
TGGGATTTC-3′) and LGALS3 (forward: 5′-CCAAAGA
GGGAATGATGTTGCC-3′, reverse: 5′-TGATTGTACT
GCAACAAGTGAGC-3′).
Galectin-3 levels in CM-P3 or CM-P30 were measured
as described previously [25]. Briefly, the concentrated CM
was analyzed using a Human Galectin-3 Platinum ELISA
(enzyme-linked immunosorbent assay) Kit (eBioscience,
San Diego, CA, USA) according to the manufacturer’s
instructions.
Galectin-3 knockdown
To knock down galectin-3 expression, P30-MSCs were
transfected with predesigned small interfering RNA (siRNA)
(Sigma-Aldrich) using Lipofectamine RNAiMAX reagent
(Invitrogen). The respective siRNA sequences of MSCs
are as follows: galectin-3 siRNA target site (MSCgal-3▼):
5′-CAC UUU AAC CCA CGC UUC AdTdT-3′ and 5′-
UGA AGC GUG GGU UAA AGU GdTdT-3′; negative
control sequences (MSCNC): 5′-UUC UCC GAA CGU
GUC ACG UTT-3′ and 5′-ACG UGA CAC GUU CGG
AGA ATT-3′.
P30-MSCs were seeded in 6-well plates, and then trans-
fected with a final concentration of 40pmol/μl MSCgal-3▼
or MSCNC and incubated for 24 h. Following the incuba-
tion and supernatant collection, total RNA or proteins
were prepared and quantified as described above.
Galectin-3 was quantified using the Human Galectin-3
Platinum ELISA Kit.
Moreover, the addition of recombinant galectin-3
(R&D Systems, Minneapolis, MN, USA) with a final con-
centration of 50-100nmol/ml to the CM of the galectin-
3 knockdown MSCs, and the proliferation of LoVo cells
were analyzed.
Western blotting for mitogen-activated protein kinase
(MAPK)
LoVo cells were incubated with CM of MSCs treated
with siRNA in the presence or absence of U0126, the
specific inhibitor of MEK1/MEK2. Proteins were ex-
tracted from LoVo cells using RIPA buffer, separated by
10 % SDS-PAGE, and transferred to Immobilon PVDF
membranes (Millipore). The membranes were blocked
with PBS containing 5 % non-fat dry milk and 0.1 %
Tween 20 overnight. After washing, the membranes
were incubated with antibodies against phosphorylated
extracellular signal–regulated kinase 1/2 (pERK1/2) and
total ERK1/2 (tERK1/2) (Cell Signaling Technology, Inc.,
Danvers, MA, USA), incubated with HRP-conjugated
secondary antibody and visualized with SuperSignal
West Pico Chemiluminescent Substrate (Millipore).
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The data are presented as the mean ± standard deviation
from ≥3 experiments analyzed using SPSS 17.0 statistical
software (IBM, New York, NY, USA). Analysis of signifi-
cance between two groups was performed with an un-
paired 2-tailed Student t-test; 1-way analysis of variance
was used for multiple comparisons. Differences were
considered significant when P < 0.05.
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